These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1650 related items for PubMed ID: 22924160

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
    Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, Dalgard O.
    Hepatology; 2011 Mar; 53(3):746-54. PubMed ID: 21374656
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H, Abe H, Seki N, Sugita T, Aida Y, Itagaki M, Sutoh S, Shimada N, Furihata T, Tsubota A, Aizawa Y.
    World J Gastroenterol; 2015 Apr 07; 21(13):3904-11. PubMed ID: 25852275
    [Abstract] [Full Text] [Related]

  • 26. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P, Maida I, Cattelan AM, Pontali E, Angeli E, Giralda M, Verucchi G, Caputo A, Iannacone C, Puoti M, Carosi G.
    J Womens Health (Larchmt); 2015 Feb 07; 24(2):159-64. PubMed ID: 25682817
    [Abstract] [Full Text] [Related]

  • 27. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
    Sperl J, Frankova S, Senkerikova R, Neroldova M, Hejda V, Volfova M, Merta D, Viklicky O, Spicak J, Jirsa M.
    World J Gastroenterol; 2015 May 14; 21(18):5496-504. PubMed ID: 25987772
    [Abstract] [Full Text] [Related]

  • 28. Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
    Bruno G, Fasano M, Saracino A, Volpe A, Bartolomeo N, Ladisa N, Maggi P, Monno L, Angarano G.
    New Microbiol; 2015 Jan 14; 38(1):21-7. PubMed ID: 25742144
    [Abstract] [Full Text] [Related]

  • 29. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
    De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, De Francesco R, Prati GM, D'Ambrosio R, Cheroni C, Donato MF, Colombo M.
    Hepatology; 2012 Feb 14; 55(2):336-42. PubMed ID: 21932415
    [Abstract] [Full Text] [Related]

  • 30. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.
    Jia Z, Ding Y, Tian S, Niu J, Jiang J.
    PLoS One; 2012 Feb 14; 7(9):e45698. PubMed ID: 23029188
    [Abstract] [Full Text] [Related]

  • 31. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.
    Hu CC, Lin CL, Chang LC, Chien CH, Chen LW, Liu CJ, Chien RN.
    BMC Infect Dis; 2015 Mar 26; 15():156. PubMed ID: 25888020
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
    Haj-Sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F.
    World J Gastroenterol; 2015 Aug 07; 21(29):8935-42. PubMed ID: 26269684
    [Abstract] [Full Text] [Related]

  • 35. Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1.
    Amanzada A, Schneider S, Moriconi F, Lindhorst A, Suermann T, van Thiel DH, Mihm S, Ramadori G.
    J Med Virol; 2012 Aug 07; 84(8):1208-16. PubMed ID: 22711348
    [Abstract] [Full Text] [Related]

  • 36. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.
    Cieśla A, Bociąga-Jasik M, Sobczyk-Krupiarz I, Głowacki MK, Owczarek D, Cibor D, Sanak M, Mach T.
    World J Gastroenterol; 2012 Sep 21; 18(35):4892-7. PubMed ID: 23002361
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-ribavirin.
    Ramos JA, Ramos AL, Hoffmann L, Perez Rde M, Coelho HS, Urményi TP, Silva R, Rondinelli E, Villela-Nogueira CA.
    Mem Inst Oswaldo Cruz; 2012 Nov 21; 107(7):888-92. PubMed ID: 23147144
    [Abstract] [Full Text] [Related]

  • 40. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
    Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J.
    J Hepatol; 2012 Sep 21; 57(3):534-40. PubMed ID: 22613000
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 83.